文献速递免疫规划慢病防控与筛查

调节免疫抑制剂用药以提高小鼠SARS-CoV-2疫苗效力

Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
PubMed 文献 · Vaccine · 2021-12-31

该研究在小鼠中评估五种免疫抑制剂(环磷酰胺、来氟米特、甲氨蝶呤、甲泼尼龙、吗替麦考酚酯)对SARS-CoV-2刺突蛋白疫苗抗体应答的影响,发现所有药物均显著降低血清抗体滴度和功能性抗体反应,暂时停用甲泼尼龙和甲氨蝶呤(而非环磷酰胺)可显著改善抗体应答。

要点

  • 五种免疫抑制剂均显著降低小鼠对SARS-CoV-2刺突蛋白疫苗的血清抗体滴度和功能性抗体反应。
  • 暂时停用甲泼尼龙和甲氨蝶呤可显著改善抗体应答,停用环磷酰胺则无此效果。
  • 作者认为自身免疫病中免疫抑制治疗可能损害SARS-CoV-2疫苗应答,暂时停药或为产生有效抗体应答所需。

核心结论

  • 通过小鼠模型原理验证实验,作者认为自身免疫病中的免疫抑制治疗可能损害对SARS-CoV-2的疫苗应答,暂时停用免疫抑制剂或为产生有效抗体疫苗应答所需。
  • 该工作为未来临床评估免疫抑制剂对人类疫苗效力的影响提供了可行性。

研究设计与样本

  • 小鼠模型原理验证实验,比较接受五种免疫抑制剂(环磷酰胺、来氟米特、甲氨蝶呤、甲泼尼龙、吗替麦考酚酯)处理与未处理小鼠在SARS-CoV-2刺突蛋白免疫前后的抗体应答和免疫细胞群体。
  • 比较持续免疫抑制治疗与暂时停用免疫抑制治疗小鼠的抗体应答。

主要发现

  • 所有测试的免疫抑制剂均显著降低免疫小鼠血清中对SARS-CoV-2刺突蛋白的抗体滴度和功能性抗体应答。
  • 暂时停用甲泼尼龙和甲氨蝶呤可显著改善抗体应答,暂时停用环磷酰胺未显著改善抗体应答。

临床怎么用

  • 作者认为,自身免疫病中通过药物治疗进行的免疫抑制可能损害对SARS-CoV-2的疫苗应答,暂时停用免疫抑制剂或为产生有效抗体疫苗应答所需。
  • 作者指出该工作为未来临床评估免疫抑制剂对人类疫苗效力的影响提供了可行性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic dramatically demonstrated the need for improved vaccination strategies and therapeutic responses to combat infectious diseases. However, the efficacy of vaccines has not yet been demonstrated in combination with commonly used immunosuppressive drug regimens. We sought to determine how common pharmaceutical drugs used in autoimmune disorders can alter immune responses to the SARS-CoV-2 spike protein vaccination. We treated mice with five immunosuppressant drugs (cyclophosphamide, leflunomide, methotrexate, methylprednisolone, and mycophenolate mofetil), each with various mechanisms of action prior to and following immunization with SARS-CoV-2 spike protein. We assessed the functionality of antibody responses to spike protein and compared immune cell populations in mice that received no treatment with those that received continuous or temporarily suspended immune suppressive therapy. All tested immunosuppressants significantly reduced the antibody titers in serum and functional antibody response against SARS-CoV-2 spike protein in immunized mice. Temporarily halting selected immunosuppressants (methylprednisolone and methotrexate, but not cyclophosphamide) improved antibody responses significantly. Through proof-of-principle experiments utilizing a mouse model, we demonstrated that immune suppression in autoimmune disorders through pharmaceutical treatments may impair vaccine response to SARS-CoV-2, and temporary suspension of immunosuppressant treatment may be necessary to mount an effective antibody vaccine response. This work provides feasibility for future clinical assessment of the impact of immunosuppressants on vaccine efficacy in humans.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Paschall AV, Ozdilek A, Briner SL, et al. Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice. Vaccine. 2021. PMID: 34991929. doi:10.1016/j.vaccine.2021.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。